For Healthcare Professionals - LUNESTA® (eszopiclone) Tablets

Please visit DailyMed for the most up-to-date information on LUNESTA®

Commercial Insurance

E-Prescribing:

Find the NPI #: NPI 1427160357 in your e-prescribing system
Select ProCare Pharmacy Care as the Specialty Pharmacy*
- 2650 SW 145th Ave, Miramar, FL 33027-6606
- *If the specialty pharmacy does not appear, please contact your e-prescribing provider to update your system
Save the Specialty Pharmacy in Your System
Transfer the Prescription

Copay Card Information

Commercially insured patients may pay as little as $5 for their prescription. Info for pharmacists below:

I am 18 or older and live in the US
I DO NOT live in Massachusetts or California
I have a valid commercial health insurance
I am NOT on Medicaid, Medicare Part D, or any other Federal insurance
Your Name

Patient Assistance Programs

Medicare / Government Insurance OR No Insurance

Medicare / government insured patients and patients without insurance may qualify to get their prescription at a lower cost.

To get started, call the Waylis Patient Access and Affordability Program at: (888) 218-8897 or fill out this r eferral form and fax to (844) 470-1931

IMPORTANT SAFETY INFORMATION AND INDICATIONS

WARNING: COMPLEX SLEEP BEHAVIORS

Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of LUNESTA®. Some of these events may result in serious injuries, including death. Discontinue LUNESTA® immediately if a patient experiences a complex sleep behavior. See full warnings and precautions

Indication & Safety Information for LUNESTA® (eszopiclone)

LUNESTA® acts quickly, so take it right before bed, and only if you have 8 hours to devote to sleep. Do not take LUNESTA® if you are allergic to anything in it. LUNESTA® should not be taken together with alcohol. Until you know how you will react to LUNESTA®, you should not drive or operate machinery. Call your doctor if your insomnia worsens or is not better within 7 to 10 days. This may mean that there is another condition causing your sleep problems. Walking, eating, driving or engaging in other activities while asleep without remembering it the next day have been reported. Other abnormal behaviors include aggressiveness, agitation, hallucinations and confusion. In depressed patients, worsening of depression including risk of suicide may occur. These risks may increase if you drink alcohol. Severe allergic reactions such as swelling of the tongue and throat occur rarely and may be fatal. Call your doctor if you experience these or any effects or reactions that concern you. LUNESTA®, like most sleep medicines, carries some risk of dependency. Side effects may include unpleasant taste, headache, morning drowsiness and dizziness.

INDICATIONS AND USAGE

LUNESTA® is indicated for the treatment of insomnia. LUNESTA® has been shown to decrease sleep latency and improve sleep maintenance.

CONTRAINDICATIONS

Patients who have experienced complex sleep behaviors after taking LUNESTA®
Known hypersensitivity to eszopiclone

WARNINGS AND PRECAUTIONS

Complex Sleep Behaviors

Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following the first or any subsequent use of LUNESTA®. Patients can be seriously injured or injure others during complex sleep behaviors. Such injuries may result in a fatal outcome. Other complex sleep behaviors (e.g., preparing and eating food, making phone calls, or having sex) have also been reported. Patients usually do not remember these events. Post-marketing reports have shown that complex sleep behaviors may occur with LUNESTA® alone at recommended dosages, with or without the concomitant use of alcohol or other CNS depressants. Discontinue LUNESTA® immediately if a patient experiences a complex sleep behavior.

CNS Depressant Effects and Next-Day Impairment

LUNESTA® is a CNS depressant and can impair daytime function in some patients at the higher doses (2 mg or 3 mg), even when used as prescribed. Prescribers should monitor for excess depressant effects, but impairment can occur in the absence of symptoms (or even with subjective improvement), and impairment may not be reliably detected by ordinary clinical exam (i.e., less than formal psychomotor testing). While pharmacodynamic tolerance or adaptation to some adverse depressant effects of LUNESTA® may develop, patients using 3 mg LUNESTA® should be cautioned against driving or engaging in other hazardous activities or activities requiring complete mental alertness the day after use.

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. Downward dose adjustment of LUNESTA® and concomitant CNS depressants should be considered.

The use of LUNESTA® with other sedative-hypnotics at bedtime or the middle of the night is not recommended.

The risk of next-day psychomotor impairment is increased if LUNESTA® is taken with less than a full night of sleep remaining (7- to 8 hours); if higher than the recommended dose is taken; if coadministered with other CNS depressants; or co-administered with other drugs that increase the blood levels of eszopiclone.

Because Lunesta can cause drowsiness and a decreased level of consciousness, patients, particularly the elderly, are at higher risk of falls.

Need to Evaluate for Comorbid Diagnoses

Because sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. Worsening of insomnia or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder. Such findings have emerged during the course of treatment with sedative/hypnotic drugs, including LUNESTA®. Because some of the important adverse effects of LUNESTA® appear to be dose related, it is important to use the lowest possible effective dose, especially in the elderly.

Severe Anaphylactic and Anaphylactoid Reactions

Rare cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including LUNESTA®. Some patients have had additional symptoms such as dyspnea, throat closing, or nausea and vomiting that suggest anaphylaxis. Some patients have required medical therapy in the emergency department. If angioedema involves the tongue, glottis or larynx, airway obstruction may occur and be fatal. Patients who develop angioedema after treatment with LUNESTA® should not be rechallenged with the drug.

Abnormal Thinking and Behavioral Changes

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of sedative/hypnotics. Some of these changes may be characterized by decreased inhibition (e.g., aggressiveness and extroversion that seem out of character), similar to effects produced by alcohol and other CNS depressants. Other reported behavioral changes have included bizarre behavior, agitation, hallucinations, and depersonalization. Amnesia and other neuropsychiatric symptoms may occur unpredictably.

It can rarely be determined with certainty whether a particular instance of the abnormal behaviors listed above is drug induced, spontaneous in origin, or a result of an underlying psychiatric or physical disorder. Nonetheless, the emergence of any new behavioral sign or symptom of concern requires careful and immediate evaluation.

Withdrawal Effects

Following rapid dose decrease or abrupt discontinuation of the use of sedative/hypnotics, there have been reports of signs and symptoms similar to those associated with withdrawal from other CNS-depressant drugs.

ADVERSE REACTIONS

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

THIS IS NOT THE FULL SAFETY INFORMATION FOR LUNESTA®. PLEASE VIEW FULL PRESCRIBING INFORMATION BELOW:

View Full LUNESTA® Prescribing Information (Waylis 1mg, 2mg) | View Full LUNESTA® Prescribing Informatio n (Sunovion 1mg, 2mg, 3mg)